Biomimetic mineralized DCPA/ anti-CD47 containing thermo-sensitive injectable hydrogel for bone-metastatic prostate cancer treatment.

ABSTRACT: Strategies that leverage the phagocytic capabilities of M1 macrophages against tumor cells are currently being investigated for cancer treatment. However, the clinical application of these strategies is significantly hampered by the severe side effects associated with conventional M1 macrophage activators. In this study, biomimetic mineralized dicalcium phosphate anhydrous (MDCPA) was synthesized using Zein as an organic template, aiming to promote M1 macrophage polarization effectively while minimizing side effects. In vitro experiments demonstrated that MDCPA can be engulfed by macrophages and induce M1 macrophage polarization. By combining the stimulation of MDCPA with a commonly used immune checkpoint inhibitor, anti-CD47 (aCD47), the macrophages exhibited the highest phagocytic

SUBMITTER: Tan S 

PROVIDER: S-EPMC11883399 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature